By Topic
European Lithium (ASX: EUR) has reached our target price already! Here's what happened.
European Lithium (ASX: EUR) hit its target price after a high-volume breakout from consolidation, rallying to A$0.39. A proposed US$835M acquisition by Critical Metals Corp and renewed interest in its lithium and rare earth assets drove the surge.
1414 Degrees (ASX:14D) Breaks Out Again on Massive Volume. Will the prior pattern repeat?
1414 Degrees is an ASX-listed cleantech company developing silicon-based thermal storage, hydrogen and battery materials; investor interest reflects Aurora and SiNTL progress, fresh $2.69 million funding, and a high-volume share-price breakout that now needs follow-through.
ClearVue Technologies (ASX: CPV): Base-Building at Key Support, Is a Trend Reversal Finally Ahead?
ClearVue Technologies develops solar glass for energy-generating buildings. A recent Cyprus contract, improved losses, and reduced dilution sparked a bounce from key support, but the broader trend remains bearish, with confirmation of reversal dependent on stronger volume and sustained commercial traction.
Racura Oncology (ASX: RAC) - A High-Risk, High-Reward Oncology Play
Racura Oncology (ASX: RAC) is executing on a bold clinical strategy centered on RC220 (bisantrene reformulation), targeting both cardioprotection and enhanced anticancer activity in combination with doxorubicin. The company has dosed its first patient in a Phase 1 solid tumor trial, expanded into South Korea, and strengthened its clinical leadership team, all while maintaining disciplined cash management (A$13.67m at June 2025) to fund operations into 2026. Though early-stage, RAC presents a compelling mid- to long-term optionality scenario for investors with conviction in cardio-oncology and specialty chemotherapy.
European Lithium (ASX: EUR) — the Push toward European Lithium Independence
European Lithium is positioning itself as a future supplier of battery-grade lithium to Europe, with the Wolfsberg Project in Austria advancing through permitting, engineering, and early-stage financing activities.
BrainChip Holdings (ASX: BRN): High-Optionality Growth Play
BrainChip is a pioneer in ultra-low-power, neuromorphic AI processing, anchored by its Akida spiking neural network architecture. With US$13.5 million cash as of June 2025, the company is funding aggressive commercialisation efforts, including next-gen Akida 2.0, Pico devices, and defence / edge-AI partnerships. While financial performance is still pre-profit, recent commercial wins, deep IP protection, and product roadmap momentum provide compelling optional upside. Key risks include cash burn, technology adoption, and scaling edge-AI deployments.
...